Cogent Biosciences, Inc. — Director's Dealing 2018

Apr 3, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Unum Therapeutics Inc. (UMRX)
CIK: 0001622229
Period of Report: 2018-04-03

Reporting Person: Atlas Venture Fund IX, L.P. (10% Owner)
Reporting Person: Atlas Venture Associates IX, L.P. (10% Owner)
Reporting Person: Atlas Venture Associates IX, LLC (10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-04-03	Common Stock	C	3184446	—	Acquired	3184446	Direct
2018-04-03	Common Stock	C	83037	—	Acquired	3267483	Direct
2018-04-03	Common Stock	P	94052	$12.00	Acquired	3361535	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-04-03	Series A Preferred Stock	$	C	3184446	Disposed		Common Stock (3184446)	Direct
2018-04-03	Series B Preferred Stock	$	C	83037	Disposed		Common Stock (83037)	Direct

Footnotes

F1: Each share automatically converted into Common Stock, for no additional consideration, on a 1.5701314513884-for-1 basis at the closing of the Issuer's initial public offering. The shares had no expiration date.

F2: The shares are held directly by Atlas Venture Fund IX, L.P. ("Atlas Venture Fund IX"). The general partner of Atlas Venture Fund IX is Atlas Venture Associates IX, L.P. ("AVA IX LP"). Atlas Venture Associates IX, LLC ("AVA IX LLC") is the general partner of AVA IX LP. Each of AVA IX LP and AVA IX LLC disclaim Section 16 beneficial ownership of the securities held by Atlas Venture Fund IX, except to the extent of its pecuniary interest therein, if any.